

Dear editor and reviewers,

Re: manuscript ID: 81925 and Title: *“The efficacy and safety of lenvatinib plus transarterial chemoembolization with or without PD-1 inhibitors in unresectable Hepatocellular Carcinoma”*

Many thanks to the editors and reviewers for their valuable comments on the manuscript entitled *“The efficacy and safety of lenvatinib plus transarterial chemoembolization with or without PD-1 inhibitors in unresectable Hepatocellular Carcinoma”* (ID: 81925). These opinions have improved the quality of our manuscript and have great guiding significance for our research. We have carefully revised the manuscript in response to the problems raised and hope to meet the requirements. The main corrections in the paper and the responses to the reviewers' comments are as following:

Responses to the reviewers' comments:

**Reviewer#1&2:**

1: The study is designed to evaluate the efficacy and safety of TACE in combination with lenvatinib and PD-1 inhibitors in the treatment of unresectable hepatocellular carcinoma. The methods are described in detail, and the results are interesting. The authors recommend that early combination of PD-1 inhibitors has promising efficacy and manageable toxicity in patients with unresectable hepatocellular carcinoma. Overall, the manuscript is very well written. No specific comments to the authors. An acceptable study. Thank you.

2: This is an interesting retrospective study about the efficacy and safety of lenvatinib plus transarterial chemoembolization with or without PD-1 inhibitors in unresectable HCC. The study is well performed and the results are interesting. The conclusion is attractive, and important to the clinicians. The reviewer recommends to accept this study after a minor editing.

**Response:** Thanks to the two reviewers for their review and recommendations of the manuscript.

**Reviewer#3:**

1. There is a minor language polishing, which should be corrected.

**Response:** Thanks to the reviewer's suggestion, we have polished the manuscript. Editing certificate is as follows.



2. Figures and tables should be edited and improved according to the journal's guideline.

**Response:** Thank the reviewer for his/her attention to details of the manuscript. We have corrected the figures and tables according to the requirements of the journal.

3. The PubMed ID should be added to the references.

**Response:** We have added the PubMed ID in the references section.

Please do not hesitate to contact us if there are any question. Thanks again to the reviewers and editor for your hard work!

Best wishes to you!

Haitao Zhao

Peking Union Medical College Hospital,

Chinese Academy of Medical Sciences and Peking Union Medical College

(CAMS &

PUMC)

November 24th, 2022